Valve-in-valve (ViV) transcatheter procedures for a failed aortic bioprosthesis are associated with a lower risk of in-hospital mortality compared with a repeat surgical aortic valve replacement, but ...
COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Thubrikar Aortic Valve, Inc. today announced successful results in an additional 5 patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) ...
Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...
In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...
PARIS, France—There is more than a twofold greater risk of death, and a significantly increased risk of major adverse cardiac events, over nearly 2 years of follow-up when patients with a bicuspid ...
Thubrikar Aortic Valve, Inc. today announced authorization from the Competent Authority of Poland to expand the TAVI-1 CE Mark trial of the Optimum Transcatheter Aortic Valve Implantation System™ ...
NORRISTOWN, Pa.--(BUSINESS WIRE)--Thubrikar Aortic Valve, Inc., announced today successful 30-day outcomes in the first two patients receiving the Optimum Transcatheter Aortic Valve (Optimum TAV™).
Transcatheter Aortic Valve Implantation (TAVI) gives broadly comparable results to conventional open surgery, with equal efficacy, faster recovery time and improved quality of life at one year, ...
In-hospital mortality for patients with left-sided infective endocarditis is significantly associated with NYHA functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results